Navitor’s Three Phase 1 Studies for NV-5138 Show Antidepressant Effects and Biomarker Impact, Supporting Further Development of Direct Activator of mTORC1 in Depression - Yahoo Finance

Submitted by Anonymous (not verified) on Thu, 09/12/2019 - 12:00

Navitor’s Three Phase 1 Studies for NV-5138 Show Antidepressant Effects and Biomarker Impact, Supporting Further Development of Direct Activator of mTORC1 in Depression  Yahoo FinanceSingle Dose NV-5138 Shows Rapid and Sustained Improvement on Core Symptoms of Depression with Favorable Safety and Tolerability in Patients with ...